Abstract:Pathogenic variants in the UBQLN2 gene cause X-linked dominant amyotrophic lateral sclerosis and/or frontotemporal dementia characterised by ubiquilin 2 aggregates in neurons of the motor cortex, hippocampus, and spinal cord. However, ubiquilin 2 neuropathology is also seen in sporadic and familial amyotrophic lateral sclerosis and/or frontotemporal dementia cases not caused by UBQLN2 pathogenic variants, particularly C9orf72 -linked cases. This makes the mechanistic role of mutant ubiquilin 2 protein and the value of ubiquilin 2 pathology for predicting genotype unclear. Here we examine a cohort of 44 genotypically diverse amyotrophic lateral sclerosis cases with or without frontotemporal dementia, including eight cases with UBQLN2 variants (resulting in p.S222G, p.P497H, p.P506S, p.T487I (two cases), and p.P497L (three cases)). Using multiplexed (5-label) fluorescent immunohistochemistry, we mapped the co-localisation of ubiquilin 2 with phosphorylated TDP-43, dipeptide repeat aggregates, and p62, in the hippocampus of controls (n = 6), or amyotrophic lateral sclerosis with or without frontotemporal dementia in sporadic (n = 20), unknown familial (n = 3), SOD1 -linked (n = 1), FUS -linked (n = 1), C9orf72 -linked (n = 5), and UBQLN2 -linked (n = 8) cases. We differentiate between i) ubiquilin 2 aggregation together with phosphorylated TDP-43 or dipeptide repeat proteins, and ii) ubiquilin 2 self-aggregation promoted by UBQLN2 pathogenic variants that cause amyotrophic lateral sclerosis/and frontotemporal dementia. Overall, we describe a hippocampal protein aggregation signature that fully distinguishes mutant from wildtype ubiquilin 2 in amyotrophic lateral sclerosis with or without frontotemporal dementia, whereby mutant ubiquilin 2 is more prone than wildtype to aggregate independently of driving factors. This neuropathological signature can be used to assess the pathogenicity of UBQLN2 gene variants and to understand the mechanisms of UBQLN2 -linked disease.

What problem does this paper attempt to address?

The paper primarily explores the pathological role of UBQLN2 gene mutations in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), and attempts to address the following key issues: 1. **Distinguishing UBQLN2-related and non-UBQLN2-related ALS/FTD cases**: By analyzing a diverse set of ALS cases (including those carrying UBQLN2 variants), the researchers aim to identify specific neuropathological features that can distinguish ALS/FTD caused by UBQLN2 mutations from other types of ALS/FTD. 2. **Understanding the behavior of UBQLN2 mutant proteins**: Specifically, the study focuses on two scenarios: first, the co-aggregation of mutant ubiquilin 2 with phosphorylated TDP-43 or dipeptide repeat proteins (DPRs); second, the self-aggregation of mutant ubiquilin 2, which is promoted by pathological variants of UBQLN2. 3. **Establishing neuropathological markers**: The researchers describe a characteristic of protein aggregation in the hippocampus that can completely distinguish the mutant from the wild-type ubiquilin 2 in ALS/FTD. This indicates that mutant ubiquilin 2 is more prone to aggregate independently, without being influenced by other driving factors. 4. **Assessing the pathogenicity of UBQLN2 gene variants**: The study of the aforementioned neuropathological features can be used to assess the pathogenicity of UBQLN2 gene variants and further understand the mechanisms of UBQLN2-related diseases. In summary, this research aims to reveal the role of UBQLN2 mutants in the pathogenesis of ALS/FTD through detailed pathological analysis, and to provide a basis for further clinical diagnosis and treatment.

Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia